Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00878709 · FLOW

Participant flow

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer · Source last updated 2021-06-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.
    id
    FG000
    title
    Neratinib
  2. description
    Patients who completed prior adjuvant trastuzumab received six 40 mg placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year.Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        197
      2. group Id
        FG001
        num Subjects
        120
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        35
      2. group Id
        FG001
        num Subjects
        33
      type
      Lost to Follow-up
    3. reasons
      1. group Id
        FG000
        num Subjects
        93
      2. group Id
        FG001
        num Subjects
        84
      type
      Other Reasons
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        1420
      2. group Id
        FG001
        num Subjects
        1420
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1095
      2. group Id
        FG001
        num Subjects
        1183
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        325
      2. group Id
        FG001
        num Subjects
        237
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.
    id
    FG000
    title
    Neratinib
  2. description
    Patients who completed prior adjuvant trastuzumab received six 40 mg placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year.Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        197
      2. group Id
        FG001
        num Subjects
        120
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        35
      2. group Id
        FG001
        num Subjects
        33
      type
      Lost to Follow-up
    3. reasons
      1. group Id
        FG000
        num Subjects
        93
      2. group Id
        FG001
        num Subjects
        84
      type
      Other Reasons
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        1420
      2. group Id
        FG001
        num Subjects
        1420
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        1095
      2. group Id
        FG001
        num Subjects
        1183
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        325
      2. group Id
        FG001
        num Subjects
        237
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice